Press release distribution service since 2001.
EuroCapital BanCorp announces its first selection for it BioTech Fund
2008-07-15
By Euro Capital / Market Strategies
EuroCapital BanCorp, ECBC, announces that its BioTech Fund has selected two American BioTech companies to be its first selections for the fund.
For_Immediate_Release:
Keywords: bank,euro capital,eurocapital,market strategies,investment,investing,costa rica,google,yahoo
Contact us: 220 Commercial Blvd Ste 206 Lauderdale by the Sea, FL 33308 Tel. 888-744-3441 Fax. 877-528-3240 www.marketstrategiescorp.com
The first is Phoenix Biosciences with Dr. Robert H. Keller, a world renowned immunologist’s who has developed a novel platform for drug development. The first application is for HIV AIDS. The HIV treatment is expected to be available at a lower cost than other treatments and due to the low side effect profile will not require a complex medical infrastructure making it ideal for treatment in the third world. Phoenix Biosciences expects to begin human trials in Tanzania, later this year. ECBC’s BioTech Fund has negotiated the purchase of 1 million shares of Phoenix’s common stock. We believe Phoenix Biosciences is an excellent prospect for an IPO in the near future.
Steve Bryant, manager of ECBC’s BioTech Fund said “the income this company will experience over the next few years make it a phenomenal hold”.
The second pick for the fund is VICOR Technologies Inc. symbol VCRT.OB, a publicly traded company, currently on the OTC bulletin board. VICOR has proprietary technology that is in the final stages of validation testing at Harvard University. The technology they have developed can predict with 100% accuracy if a patient will suffer from sudden cardiac arrest or other cardiac irregularity 6 months in advance. VICOR has also developed early prediction testing for stroke and Alzheimer’s (more news on that coming soon).
ECBC shall upon conclusion of funding, from its European syndicate partners go on the bid, and accumulate VICOR stock from all available sources for the bank and its investors. “These devices and new technologies will save thousands of lives and the market for them will be immense”, said Steve Bryant, manager of ECBC’s “BioTech Fund”. Bryant said also “this is what we do, find the companies that will be making tomorrow’s headlines, accumulate them early on at a great value and wait patiently”.
The return on this type of positioning, with these types of situations is expected to be a huge multiple not a percentage. We are not only identifying emerging Biotech’s with huge impact, but with the funding we will make available to them though our Bank we can help insure their success. Bryant said.
For further information you may contact our marketing Company, Market Strategies Corp. S.A. at 1-888-744-3441.
####
For more information:Steve Bryant, manager of ECBC’s BioTech Fund said “the income this company will experience over the next few years make it a phenomenal hold”.
The second pick for the fund is VICOR Technologies Inc. symbol VCRT.OB, a publicly traded company, currently on the OTC bulletin board. VICOR has proprietary technology that is in the final stages of validation testing at Harvard University. The technology they have developed can predict with 100% accuracy if a patient will suffer from sudden cardiac arrest or other cardiac irregularity 6 months in advance. VICOR has also developed early prediction testing for stroke and Alzheimer’s (more news on that coming soon).
ECBC shall upon conclusion of funding, from its European syndicate partners go on the bid, and accumulate VICOR stock from all available sources for the bank and its investors. “These devices and new technologies will save thousands of lives and the market for them will be immense”, said Steve Bryant, manager of ECBC’s “BioTech Fund”. Bryant said also “this is what we do, find the companies that will be making tomorrow’s headlines, accumulate them early on at a great value and wait patiently”.
The return on this type of positioning, with these types of situations is expected to be a huge multiple not a percentage. We are not only identifying emerging Biotech’s with huge impact, but with the funding we will make available to them though our Bank we can help insure their success. Bryant said.
For further information you may contact our marketing Company, Market Strategies Corp. S.A. at 1-888-744-3441.
####
Keywords: bank,euro capital,eurocapital,market strategies,investment,investing,costa rica,google,yahoo
Contact us: 220 Commercial Blvd Ste 206 Lauderdale by the Sea, FL 33308 Tel. 888-744-3441 Fax. 877-528-3240 www.marketstrategiescorp.com